Stem cell transplantation for indolent lymphoma

Thomas, 1999, A history of haemopoietic cell transplantation, Br J Haematol, 105, 330, 10.1111/j.1365-2141.1999.01337.x Pavlu, 2010, Three decades of transplantation for chronic myeloid leukemia: what have we learnt?, Blood Ratanatharathorn, 1994, Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma, Blood, 84, 1050, 10.1182/blood.V84.4.1050.1050 Jones, 1991, Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation, Blood, 77, 649, 10.1182/blood.V77.3.649.649 Van Besien, 1995, Allogeneic bone marrow transplantation for refractory and recurrent low grade lymphoma — the case for aggressive management, J Clin Oncol, 13, 1096, 10.1200/JCO.1995.13.5.1096 Van Besien, 1996, Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology, Am J Med, 100, 299, 10.1016/S0002-9343(97)89488-0 van Besien, 1998, Allogeneic bone marrow transplantation for low grade lymphoma, Blood, 92, 1832 Toze, 2000, Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia, Bone Marrow Transplant, 25, 605, 10.1038/sj.bmt.1702191 Stein, 1999, High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin, Bone Marrow Transplant, 23, 227, 10.1038/sj.bmt.1701556 Peniket, 2003, An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation, Bone Marrow Transplant, 31, 667, 10.1038/sj.bmt.1703891 Oliansky, 2010, The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review, Biol Blood Marrow Transplant, 16, 443, 10.1016/j.bbmt.2010.01.008 van Besien, 2009, Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy, Hematology. Am. Soc. Hematol. Educ. Program, 610, 10.1182/asheducation-2009.1.610 van Besien, 2007, Follicular lymphoma: a historical overview, Leuk Lymphoma, 48, 232, 10.1080/10428190601059746 Cutler, 2005, Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens, Biol Blood Marrow Transplant, 11, 383, 10.1016/j.bbmt.2005.02.006 Hari, 2008, Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning, Biol Blood Marrow Transplant, 14, 236, 10.1016/j.bbmt.2007.11.004 Sorror, 2008, Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia, Blood, 111, 446, 10.1182/blood-2007-07-098483 Estey, 2007, Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), Blood, 109, 1395, 10.1182/blood-2006-05-021907 Hardy, 2007, Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation, Br. J. Haematol., 139, 824, 10.1111/j.1365-2141.2007.06862.x Garcia, 2010, Pre-donor evaluation of an HLA matched sibling identifies a novel inherited RUNX1 mutation encoding a missense mutation found outside of the RUNT domain in familial platelet disorder, Blood, 116, 2709, 10.1182/blood.V116.21.2709.2709 Lee, 2007, High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation, Blood, 10.1182/blood-2007-06-097386 van Besien, 2009, Unrelated donor hematopoietic cell transplantation for non-Hodgkin lymphoma: long-term outcomes, Biol Blood Marrow Transplant, 15, 554, 10.1016/j.bbmt.2009.01.012 Thomson, 2010, T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma, J Clin Oncol, 28, 3695, 10.1200/JCO.2009.26.9100 Dew, 2008, Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options, Biol Blood Marrow Transplant, 14, 938, 10.1016/j.bbmt.2008.06.005 Gooley, 2010, Reduced mortality after allogeneic hematopoietic-cell transplantation, N Engl J Med, 363, 2091, 10.1056/NEJMoa1004383 van Besien, 2003, Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma, Blood, 102, 3521, 10.1182/blood-2003-04-1205 Artz, 2006, Performance status and comorbidity predict transplant related mortality after allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, 12, 954, 10.1016/j.bbmt.2006.05.015 Sorror, 2008, Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation, Cancer, 112, 1992, 10.1002/cncr.23375 Armand, 2008, A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 14, 28, 10.1016/j.bbmt.2007.07.016 Artz, 2008, Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, 14, 1209, 10.1016/j.bbmt.2008.08.004 Pavlu, 2010, Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase, Blood, 115, 4018, 10.1182/blood-2010-01-263624 Remberger, 2010, C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation, Int J Hematol, 92, 161, 10.1007/s12185-010-0632-7 McNeer, 2010, Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 16, 350, 10.1016/j.bbmt.2009.10.036 van Besien, 2003, Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma, Blood, 102, 3521, 10.1182/blood-2003-04-1205 Kenkre, 2010, T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed lymphoma. Predictors for survival after transplant relapse, Leuk Lymphoma Lambert, 2010, Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma, Blood, 115, 2763, 10.1182/blood-2009-11-255182 Khouri, 2008, Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab, Blood, 111, 5530, 10.1182/blood-2008-01-136242 van Besien, 2008, Nonmyeloablative conditioning for relapsed follicular lymphoma, Blood, 112, 2585-258a, 10.1182/blood-2008-06-162800 Vigouroux, 2007, Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC), Haematologica, 92, 627, 10.3324/haematol.10924 Robinson, 2002, Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation, Blood, 100, 4310, 10.1182/blood-2001-11-0107 Armand, 2008, Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning, J Clin Oncol, 26, 5767, 10.1200/JCO.2008.17.7279 Gopal, 2006, Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy, Biol Blood Marrow Transplant, 12, 697, 10.1016/j.bbmt.2006.03.014 Kohrt, 2009, TLI and ATG conditioning with low risk of graft-versus-host disease retains anti-tumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors, Blood, 10.1182/blood-2009-03-211441 van Besien, 2009, Phase I–II study of clofarabine-melphalan-alemtuzumab (CMA) conditioning for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies: determination of MTD and outcomes, Blood, 114, 197, 10.1182/blood.V114.22.197.197 Bethge, 2010, Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study, Blood, 116, 1795, 10.1182/blood-2010-02-270538 Kersey, 2010, The role of allogeneic-cell transplantation in leukemia, N Engl J Med, 363, 2158, 10.1056/NEJMe1010818 Bhatia, 2007, Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study, Blood, 110, 3784, 10.1182/blood-2007-03-082933 Baker, 2010, Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study, Leukemia, 24, 2039, 10.1038/leu.2010.210 Bacigalupo, 2006, Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation, Biol Blood Marrow Transplant, 12, 560, 10.1016/j.bbmt.2005.12.034 Novitzky, 2007, Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies, Biol Blood Marrow Transplant, 13, 107, 10.1016/j.bbmt.2006.09.004 Ingram, 2008, Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma, Br J Haematol, 141, 235, 10.1111/j.1365-2141.2008.07067.x van Besien, 2009, Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence, Leuk Lymphoma, 50, 1809, 10.3109/10428190903200790 Armand, 2008, Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome, Biol Blood Marrow Transplant, 14, 418, 10.1016/j.bbmt.2008.01.008 Van Besien, 1997, Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effects, Bone Marrow Transplant, 19, 977, 10.1038/sj.bmt.1700781 Bloor, 2008, High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma, Biol Blood Marrow Transplant, 14, 50, 10.1016/j.bbmt.2007.04.013